Since the beginning of the HIV epidemic forty years ago, over 40 million people have died as a result from the infection. Today, over 38 million individuals continue to live with HIV, most of them situated in sub-Saharan Africa. While a lot of progress is made in the field of HIV research, scientists are still looking for a cure. Currently, the standard treatment is antiretroviral therapy (ART), which supresses the virus in a way that it cannot weaken the immune system. However, ART has several disadvantages such as its cost, the need to be taken lifelong, and has some side-effects. Moreover, the global ART coverage rate was only 74.7% in 2021, revealing that millions of infected individuals have no access to effective medication, most of them living in low- and middle-income countries. Without continuous treatment, the virus will slowly progress to the AIDS stage, ultimately resulting in death. Effective and available HIV treatment will immensely affect the quality of life of patients, significantly reducing morbidity and mortality rates. Additionally, it would reduce the economic burden associated with the ongoing healthcare costs. Individuals living with HIV often endure societal prejudice and discrimination, which further adds to the challenges they face. Effective treatment would not only improve physical health, but also reduce the HIV-related stigma and promote greater acceptance, inclusivity, and equality withing society. The aim of this thesis is to develop a protein-based targeted therapy for functional cure of HIV. The strategy is based on recent successes using a similar approach in the oncology field aiming at helping the immune system to eliminate of HIV reservoirs.